

- outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery [J]. *Ann Oncol*, 2007,18(2):299-304. DOI: 0.1093/annonc/mdl386.
- [237] Yu Q, Zhang L, Fan S, et al. The significance of transarterial chemoembolization combined with systemic chemotherapy for patients with KRAS wild-type unresectable metachronous colorectal carcinoma with liver metastases [J]. *J Cancer Res Ther*, 2016,12(Supplement):C205-C211. DOI:10.4103/0973-1482.200603.
- [238] Zelek L, Bugat R, Cherqui D, et al. Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial)[J]. *Ann Oncol*, 2003,14(10):1537-1542.
- [239] Adam R, Avisar E, Ariche A, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal[J]. *Ann Surg Oncol*, 2001,8(4):347-353.
- [240] Suzuki C, Blomqvist L, Sundin A, et al. The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy [J]. *Ann Oncol*, 2012,23 (4):948-954. DOI: 10.1093/annonc/mdr350.
- [241] Ye LC, Wei Y, Zhu DX, et al. Impact of early tumor shrinkage on clinical outcome in wild-type-KRAS colorectal liver metastases treated with cetuximab [J]. *J Gastroenterol Hepatol*, 2015,30(4):674-679. DOI:10.1111/jgh.12847.
- [242] Piessevaux H, Buyse M, Schlichting M, et al. Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab [J]. *J Clin Oncol*, 2013, 31(30):3764-3775. DOI:10.1200/JCO.2012.42.8532.
- [243] Alberts SR, Horvath WL, Sternfeld WC, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study[J]. *J Clin Oncol*, 2005,23(36):9243-9249. DOI:10.1200/JCO.2005.07.740.
- [244] Quenet F NB, Rivoire M. Resection of previously unresectable liver metastases from colorectal cancer after chemotherapy with CPT-11/L-ohp/LV5FU (Folfinox): A prospective phase II trial[J]. *Proc Am Soc Clin Oncol*, 2004,23:Abstract 3613.
- [245] Giacchetti S, Itzhaki M, Gruia G, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery[J]. *Ann Oncol*, 1999,10(6):663-669.
- [246] Bruera G, Santomaggio A, Cannita K, et al. "Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (Flr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study [J]. *BMC Cancer*, 2010,10:567. DOI:10.1186/1471-2407-10-567.
- [247] Wong R, Cunningham D, Barbachano Y, et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection [J]. *Ann Oncol*, 2011,22(9):2042-2048. DOI:10.1093/annonc/mdq714.
- [248] Van Cutsem E, Lenz HJ, Köhne CH, et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer[J]. *J Clin Oncol*, 2015,33(7):692-700. DOI:10.1200/JCO.2014.59.4812.
- [249] Modest DP, Stintzing S, von WLF, et al. Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer [J]. *J Clin Oncol*, 2015, 33(32):3718-3726. DOI: 10.1200/JCO.2015.61.2887.
- [250] Azadeh P, Mortazavi N, Tahmasebi A, et al. Cetuximab Plus Various Chemotherapy Regimens for Patients with KRAS Wild-Type Metastatic Colorectal Cancer[J]. *Chemotherapy*, 2016, 61(1):51-56. DOI:10.1159/000440693.
- [251] Cassidy J, Cunningham D. Surgery with curative intent in patients (pts) treated with first-line chemotherapy (CT) + bevacizumab (BEV) for metastatic colorectal cancer (mCRC): first BEAT and NO16966 [J]. *J Clin Oncol*, 2008,26 Abstract 4022.
- [252] Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer [J]. *J Clin Oncol*, 2009,27(5):663-671. DOI:10.1200/JCO.2008.20.8397.
- [253] Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study[J]. *J Clin Oncol*, 2010,28 (31):4697-4705. DOI:10.1200/JCO.2009.27.4860.
- [254] Basso M, Dadduzio V, Ardito F, et al. Conversion Chemotherapy for Technically Unresectable Colorectal Liver Metastases: A Retrospective, STROBE-Compliant, Single-Center Study Comparing Chemotherapy Alone and Combination Chemotherapy With Cetuximab or Bevacizumab [J]. *Medicine (Baltimore)*, 2016,95(20):e3722. DOI:10.1097/MD.00000000000003722.
- [255] Karapetis CS, Jonker D, Daneshmand M, et al. PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17 [J]. *Clin Cancer Res*, 2014,20(3):744-753. DOI:10.1158/1078-0432.CCR-13-0606.
- [256] Souglakos J, Androulakis N, Syrigos K, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)[J]. *Br J Cancer*, 2006,

- 94(6):798-805. DOI:10.1038/sj.bjc.6603011.
- [257] Garufi C, Torsello A, Tumolo S, et al. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial [J]. *Br J Cancer*, 2010,103(10):1542-1547. DOI:10.1038/sj.bjc.6605940.
- [258] Stein A, Atanackovic D, Hildebrandt B, et al. Upfront FOLFOXIRI +bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer[J]. *Br J Cancer*, 2015, 113(6):872-877. DOI: 10.1038/bjc.2015.299.
- [259] Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study [J]. *Lancet Oncol*, 2015, 16(13):1306-1315. DOI:10.1016/S1470-2045(15)00122-9.
- [260] Tomasello G, Petrelli F, Ghidini M, et al. FOLFOXIRI plus bevacizumab as conversion therapy for patients with initially unresectable metastatic colorectal cancer: a systematic review and pooled analysis [J]. *JAMA Oncol*, 2017,3(7):e170278. DOI: 10.1001/jamaoncol.2017.0278.
- [261] Esin E, Yalcin S. Maintenance strategy in metastatic colorectal cancer: A systematic review [J]. *Cancer Treat Rev*, 2016,42:82-90. DOI:10.1016/j.ctrv.2015.10.012.
- [262] Hegewisch-Becker S, Graeven U, Lerchenmüller CA, et al. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial [J]. *Lancet Oncol*, 2015,16(13):1355-1369. DOI:10.1016/S1470-2045(15)00042-X.
- [263] Simkens LH, van Tinteren H, May A, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group [J]. *Lancet*, 2015,385(9980):1843-1852. DOI:10.1016/S0140-6736(14)62004-3.
- [264] KKH G, Elias SG, van Tinteren H, et al. Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study [J]. *Ann Oncol*, 2017,28(9):2128-2134. DOI:10.1093/annonc/mdx322.
- [265] Stein A, Schwenke C, Folprecht G, et al. Effect of application and intensity of bevacizumab-based maintenance after induction chemotherapy with bevacizumab for metastatic colorectal cancer: a meta-analysis [J]. *Clin Colorectal Cancer*, 2016, 15(2):e29-e39. DOI:10.1016/j.clcc.2015.12.005.
- [266] Xu RH, Muro K, Morita S, et al. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial [J]. *Lancet Oncol*, 2018,19(5):660-671. DOI:10.1016/S1470-2045(18)30140-2.
- [267] Ducreux M, Malka D, Mendiboure J, et al. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial [J]. *Lancet Oncol*, 2011,12(11):1032-1044. DOI:10.1016/S1470-2045(11)70199-1.
- [268] Koopman M, Antonini NF, Douma J, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial [J]. *Lancet*, 2007,370(9582):135-142. DOI:10.1016/S0140-6736(07)61086-1.
- [269] Seymour MT, Maughan TS, Ledermann JA, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial [J]. *Lancet*, 2007,370(9582):143-152. DOI:10.1016/S0140-6736(07)61087-3.
- [270] Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial [J]. *Lancet*, 2013,381(9863):303-312. DOI:10.1016/S0140-6736(12)61900-X.
- [271] Li J, Qin S, Xu R, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial [J]. *Lancet Oncol*, 2015,16(6):619-629. DOI:10.1016/S1470-2045(15)70156-7.
- [272] Bennouna J, Borg C, Delord JP, et al. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study [J]. *Clin Colorectal Cancer*, 2012,11(1):38-44. DOI:10.1016/j.clcc.2011.05.002.
- [273] Iwamoto S, Hazama S, Kato T, et al. Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study [J]. *Anticancer Res*, 2014,34(4):1967-1973.
- [274] Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J]. *N Engl J Med*, 2004,350(23):2335-2342. DOI:10.1056/NEJMoa032691.
- [275] Chan DL, Alzahrani NA, Morris DL, et al. Systematic review and meta-analysis of hepatic arterial infusion chemotherapy as bridging therapy for colorectal liver metastases [J]. *Surg Oncol*, 2015,24(3):162-171. DOI:10.1016/j.suronc.2015.06.014.
- [276] D'Angelica MI, Correa-Gallego C, Paty PB, et al. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes [J]. *Ann Surg*, 2015,261(2):353-360. DOI:10.1097/SLA.0000000000000614.

- [277] McAuliffe JC, Qadan M, D'Angelica MI. Hepatic resection, hepatic arterial infusion pump therapy, and genetic biomarkers in the management of hepatic metastases from colorectal cancer [J]. *J Gastrointest Oncol*, 2015, 6(6):699-708. DOI:10.3978/j.issn.2078-6891.2015.081.
- [278] Liu DM, Thakor AS, Baerlocher M, et al. A review of conventional and drug-eluting chemoembolization in the treatment of colorectal liver metastases; principles and proof [J]. *Future Oncol*, 2015, 11(9):1421-1428. DOI:10.2217/fon.15.3.
- [279] Noshier JL, Ahmed I, Patel AN, et al. Non-operative therapies for colorectal liver metastases [J]. *J Gastrointest Oncol*, 2015, 6(2):224-240. DOI:10.3978/j.issn.2078-6891.2014.065.
- [280] Mocellin S, Pasquali S, Nitti D. Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer [J]. *Cochrane Database Syst Rev*, 2009, (3):CD007823. DOI:10.1002/14651858.CD007823.pub2.
- [281] Kemeny NE, Melendez FD, Capanu M, et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma [J]. *J Clin Oncol*, 2009, 27(21):3465-3471. DOI:10.1200/JCO.2008.20.1301.
- [282] Hammill CW, Billingsley KG, Cassera MA, et al. Outcome after laparoscopic radiofrequency ablation of technically resectable colorectal liver metastases [J]. *Ann Surg Oncol*, 2011, 18(7):1947-1954. DOI:10.1245/s10434-010-1535-9.
- [283] Livraghi T, Solbiati L, Meloni MF, et al. Treatment of focal liver tumors with percutaneous radio-frequency ablation; complications encountered in a multicenter study [J]. *Radiology*, 2003, 226(2):441-451.
- [284] Feliberti EC, Wagman LD. Radiofrequency ablation of liver metastases from colorectal carcinoma [J]. *Cancer Control*, 2006, 13(1):48-51. DOI:10.1177/107327480601300107.
- [285] Siperstein AE, Berber E, Ballem N, et al. Survival after radiofrequency ablation of colorectal liver metastases; 10-year experience [J]. *Ann Surg*, 2007, 246(4):559-565-567. DOI:10.1097/SLA.0b013e318155a7b6.
- [286] Berber E, Tsinberg M, Tellioglu G, et al. Resection versus laparoscopic radio frequency thermal ablation of solitary colorectal liver metastasis [J]. *J Gastrointest Surg*, 2008, 12(11):1967-1972. DOI:10.1007/s11605-008-0622-8.
- [287] Knudsen AR, Kannerup AS, Mortensen FV, et al. Radiofrequency ablation of colorectal liver metastases downstaged by chemotherapy [J]. *Acta Radiol*, 2009, 50(7):716-721. DOI:10.1080/02841850902991634.
- [288] Brouquet A, Andreou A, Vauthey JN. The management of solitary colorectal liver metastases [J]. *Surgeon*, 2011, 9(5):265-272. DOI:10.1016/j.surge.2010.12.005.
- [289] Kawaguchi Y, Hasegawa K, Saiura A, et al. Surgical resection for local recurrence after radiofrequency ablation for colorectal liver metastasis is more extensive than primary resection [J]. *Scand J Gastroenterol*, 2014, 49(5):569-575. DOI:10.3109/00365521.2014.893013.
- [290] Bilchik AJ, Wood TF, Allegra DP. Radiofrequency ablation of unresectable hepatic malignancies; lessons learned [J]. *Oncologist*, 2001, 6(1):24-33.
- [291] Curley SA, Izzo F. Radiofrequency ablation of hepatocellular carcinoma [J]. *Minerva Chir*, 2002, 57(2):165-176.
- [292] Lu DS, Raman SS, Limanond P, et al. Influence of large peritumoral vessels on outcome of radiofrequency ablation of liver tumors [J]. *J Vasc Interv Radiol*, 2003, 14(10):1267-1274.
- [293] Elias D, Di PD, Gachot B, et al. Liver abscess after radiofrequency ablation of tumors in patients with a biliary tract procedure [J]. *Gastroenterol Clin Biol*, 2006, 30(6-7):823-827.
- [294] Zhang X, Zhou L, Chen B, et al. Microwave ablation with cooled-tip electrode for liver cancer: an analysis of 160 cases [J]. *Minim Invasive Ther Allied Technol*, 2008, 17(5):303-307. DOI:10.1080/13645700802383926.
- [295] Shono Y, Tabuse K, Tsuji T, et al. Microwave coagulation therapy for unresectable colorectal metastatic liver tumor [J]. *Gan To Kagaku Ryoho*, 2002, 29(6):856-859.
- [296] Grundmann RT, Hermanek P, Merkel S, et al. Diagnosis and treatment of colorectal liver metastases - workflow [J]. *Zentralbl Chir*, 2008, 133(3):267-284. DOI:10.1055/s-2008-1076796.
- [297] Seifert JK, Junginger T. Prognostic factors for cryotherapy of colorectal liver metastases [J]. *Eur J Surg Oncol*, 2004, 30(1):34-40.
- [298] Chen YY, Perera DS, Yan TD, et al. Applying Fong's CRS liver score in patients with colorectal liver metastases treated by cryotherapy [J]. *Asian J Surg*, 2006, 29(4):238-241. DOI:10.1016/S1015-9584(09)60095-6.
- [299] Seifert JK, Junginger T. Cryotherapy for liver tumors: current status, perspectives, clinical results, and review of literature [J]. *Technol Cancer Res Treat*, 2004, 3(2):151-163. DOI:10.1177/153303460400300208.
- [300] Gignoux BM, Ducerf C, Mabrut JY, et al. Cryosurgery of primary and metastatic cancers of the liver [J]. *Ann Chir*, 2001, 126(10):950-959.
- [301] Austin-Seymour MM, Chen GT, Castro JR, et al. Dose volume histogram analysis of liver radiation tolerance [J]. *Int J Radiat Oncol Biol Phys*, 1986, 12(1):31-35.
- [302] Eble MJ, Gademann G, Wannemacher M. The value of radiotherapy for liver metastases [J]. *Strahlenther Onkol*, 1993, 169(8):459-468.
- [303] Ingold JA, Reed GB, Kaplan HS, et al. Radiation Hepatitis. *Am J Roentgenol Radium Ther Nucl Med*, 1965, 93:200-208.
- [304] Yeo SG, Kim DY, Kim TH, et al. Whole-liver radiotherapy for end-stage colorectal cancer patients with massive liver metastases and advanced hepatic dysfunction [J]. *Radiat Oncol*, 2010, 5:97. DOI:10.1186/1748-717X-5-97.
- [305] Rusthoven KE, Kavanagh BD, Cardenas H, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases [J]. *J Clin Oncol*, 2009, 27(10):1572-1578. DOI:10.1200/JCO.2008.19.6329.

- [306] Mohiuddin M, Chen E, Ahmad N. Combined liver radiation and chemotherapy for palliation of hepatic metastases from colorectal cancer [J]. *J Clin Oncol*, 1996,14 (3):722-728. DOI:10.1200/JCO.1996.14.3.722.
- [307] Colletini F, Schnapauff D, Poellinger A, et al. Percutaneous CT-guided high-dose brachytherapy (CT-HDRBT) ablation of primary and metastatic lung tumors in nonsurgical candidates [J]. *Rofo*, 2012,184(4):316-323. DOI:10.1055/s-0031-1299101.
- [308] Comito T, Cozzi L, Clerici E, et al. Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach [J]. *BMC Cancer*, 2014,14:619. DOI:10.1186/1471-2407-14-619.
- [309] Filippi AR, Badellino S, Guarneri A, et al. Outcomes of single fraction stereotactic ablative radiotherapy for lung metastases [J]. *Technol Cancer Res Treat*, 2014,13(1):37-45. DOI:10.7785/tert.2012.500355.
- [310] Tselis N, Ferentinos K, Kolotas C, et al. Computed tomography-guided interstitial high-dose-rate brachytherapy in the local treatment of primary and secondary intrathoracic malignancies [J]. *J Thorac Oncol*, 2011,6(3):545-552. DOI:10.1097/JTO.0b013e318208c7a3.
- [311] Peters N, Wieners G, Pech M, et al. CT-guided interstitial brachytherapy of primary and secondary lung malignancies: results of a prospective phase II trial [J]. *Strahlenther Onkol*, 2008,184(6):296-301. DOI:10.1007/s00066-008-1718-5.
- [312] Dawood O, Mahadevan A, Goodman KA. Stereotactic body radiation therapy for liver metastases [J]. *Eur J Cancer*, 2009,45(17):2947-2959. DOI:10.1016/j.ejca.2009.08.011.
- [313] Lee MT, Kim JJ, Dinniwel R, et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases [J]. *J Clin Oncol*, 2009,27 (10):1585-1591. DOI: 10.1200/JCO.2008.20.0600.
- [314] Agolli L, Bracci S, Nicosia L, et al. Lung Metastases Treated With Stereotactic Ablative Radiation Therapy in Oligometastatic Colorectal Cancer Patients: Outcomes and Prognostic Factors After Long-Term Follow-Up [J]. *Clin Colorectal Cancer*, 2017,16(1):58-64. DOI:10.1016/j.clcc.2016.07.004.
- [315] Chang DT, Swaminath A, Kozak M, et al. Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis [J]. *Cancer*, 2011,117 (17):4060-4069. DOI: 10.1002/encr.25997.
- [316] Hong TS, Ritter MA, Tomé WA, et al. Intensity-modulated radiation therapy: emerging cancer treatment technology [J]. *Br J Cancer*, 2005,92 (10):1819-1824. DOI:10.1038/sj.bjc.6602577.
- [317] Meyer J, Czito B, Yin FF, et al. Advanced radiation therapy technologies in the treatment of rectal and anal cancer: intensity-modulated photon therapy and proton therapy [J]. *Clin Colorectal Cancer*, 2007,6 (5):348-356. DOI: 10.3816/CCC.2007.n.003.
- [318] Topkan E, Onal HC, Yavuz MN. Managing liver metastases with conformal radiation therapy [J]. *J Support Oncol*, 2008,6 (1):9-13, 15.
- [319] Schefer TE, Kavanagh BD, Timmerman RD, et al. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases [J]. *Int J Radiat Oncol Biol Phys*, 2005,62(5):1371-1378. DOI:10.1016/j.ijrobp.2005.01.002.
- [320] Goodman KA, Wiegner EA, Maturen KE, et al. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies [J]. *Int J Radiat Oncol Biol Phys*, 2010,78(2):486-493. DOI:10.1016/j.ijrobp.2009.08.020.
- [321] Katz AW, Carey-Sampson M, Muhs AG, et al. Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases [J]. *Int J Radiat Oncol Biol Phys*, 2007,67(3):793-798. DOI:10.1016/j.ijrobp.2006.10.025.
- [322] Gruenberger B, Tamandl D, Puhalla H, et al. Bevacizumab plus XELOX as neoadjuvant chemotherapy for patients with potentially curable metastatic colorectal cancer [J]. *J Clin Oncol*, 2007,25(18 suppl):179s.
- [323] Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE) [J]. *J Clin Oncol*, 2008,26 (33):5326-5334. DOI: 10.1200/JCO.2008.16.3212.
- [324] Welch S, Spithoff K, Rumble RB, et al. Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review [J]. *Ann Oncol*, 2010,21(6):1152-1162. DOI:10.1093/annonc/mdp533.
- [325] Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer [J]. *N Engl J Med*, 2009,360(6):563-572. DOI:10.1056/NEJMoa0808268.
- [326] Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase III B trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer [J]. *J Clin Oncol*, 2009,27(5):672-680. DOI: 10.1200/JCO.2008.19.8135.
- [327] Spigel DR, Greco FA, Waterhouse D, et al. Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer [J]. *Clin Adv Hematol Oncol*, 2010,8(7):480-485, 498.
- [328] Sato Y, Matsusaka S, Suenaga M, et al. Cetuximab could be more effective without prior bevacizumab treatment in metastatic colorectal cancer patients [J]. *Onco Targets Ther*, 2015,8:3329-3336. DOI:10.2147/OTT.S89241.
- [329] Raoul JL, Van Laethem JL, Peeters M, et al. Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study [J]. *BMC Cancer*, 2009,9:112. DOI: 10.1186/1471-2407-9-112.
- [330] Van Cutsem E, Köhne CH, Lúg I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status [J]. *J Clin Oncol*, 2011,29 (15):2011-2019. DOI:10.1200/JCO.2010.33.5091.

- [331] Pietrantonio F, Cremolini C, Petrelli F, et al. First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis [J]. *Crit Rev Oncol Hematol*, 2015, 96(1):156-166. DOI:10.1016/j.critrevonc.2015.05.016.
- [332] De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab [J]. *Ann Oncol*, 2008, 19(3):508-515.
- [333] Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer [J]. *N Engl J Med*, 2009, 359(17):1757-1765. DOI: 10.1056/NEJMoa0804385.
- [334] Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J]. *J Clin Oncol*, 2008, 26(10):1626-1634. DOI:10.1200/JCO.2007.14.7116.
- [335] Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer; results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial [J]. *J Clin Oncol*, 2010, 28(3):466-474. DOI:10.1200/JCO.2009.23.3452.
- [336] Price TJ, Hardingham JE, Lee CK, et al. Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer [J]. *J Clin Oncol*, 2011, 29(19):2675-2682. DOI: 10.1200/JCO.2010.34.5520.
- [337] Saridaki Z, Papadatos-Pastos D, Tzardi M, et al. BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome [J]. *Br J Cancer*, 2010, 102(12):1762-1768. DOI:10.1038/sj.bjc.6605694.
- [338] Tveit K, Guren T. Randomized phase III study of 5-Fluorouracil/folinic acid/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: The NORDIC VII study (NCT00145314) [J]. *Ann Oncol*, 2010, 21:pLBA 20.
- [339] Package Insert. Cetuximab (Erbix<sup>®</sup>). Branchburg, NJ: ImClone Systems Incorporated, 2013.
- [340] Hoff PM, Eng C, Adinin RB, et al. Preliminary results from a phase II study of FOLFIRI plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC) [C]. *ASCO annual meeting proceedings*, 2006, 24(Suppl):165S.
- [341] Van Cutsem E, Rivera F, Berry S, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study [J]. *Ann Oncol*, 2009, 20(11):1842-1847. DOI:10.1093/annonc/mdp233.
- [342] López R, Salgado M, Reboredo M, et al. A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer [J]. *Br J Cancer*, 2010, 103(10):1536-1541. DOI:10.1038/sj.bjc.6605938.
- [343] Chaudhury P, Hassanain M, Bouganin N, et al. Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis [J]. *HPB (Oxford)*, 2010, 12(1):37-42. DOI:10.1111/j.1477-2574.2009.00119.x.
- [344] Jang HJ, Kim BJ, Kim JH, et al. The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials [J]. *Oncotarget*, 2017, 8(42):73009-73016. DOI: 10.18632/oncotarget.20314.
- [345] Cartwright TH, Yim YM, Yu E, et al. Survival outcomes of bevacizumab beyond progression in metastatic colorectal cancer patients treated in US community oncology [J]. *Clin Colorectal Cancer*, 2012, 11(4):238-246. DOI:10.1016/j.clcc.2012.05.005.
- [346] Hamamoto Y, Yamaguchi T, Nishina T, et al. A phase I/II study of XELIRI plus bevacizumab as second-line chemotherapy for Japanese patients with metastatic colorectal cancer (BIX study) [J]. *Oncologist*, 2014, 19(11):1131-1132. DOI:10.1634/theoncologist.2014-0159.
- [347] Masi G, Salvatore L, Boni L, et al; BEBYP Study Investigators. Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial [J]. *Ann Oncol*, 2015, 26(4):724-730. DOI:10.1093/annonc/mdv012.
- [348] Bennouna J, Phelip JM, André T, et al. Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT) [J]. *Clin Colorectal Cancer*, 2017, 16(2):129-140. e4. DOI: 10.1016/j.clcc.2016.07.013.
- [349] Yin C, Ma G, Rong Y, et al. The Efficacy of Bevacizumab in Different Line Chemotherapy for Chinese Patients with Metastatic Colorectal Cancer [J]. *J Cancer*, 2016, 7(13):1901-1906. DOI:10.7150/jca.15802.
- [350] D'Angelica M, Kornprat P, Gonen M, et al. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study [J]. *Ann Surg Oncol*, 2007, 14(2):759-765. DOI:10.1245/s10434-006-9074-0.
- [351] Reddy SK, Morse MA, Hurwitz HI, et al. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases [J]. *J Am Coll Surg*, 2008, 206(1):96-106. DOI:10.1016/j.jamcollsurg.2007.06.290.
- [352] Starlinger P, Alidzanovic L, Schauer D, et al. Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation [J]. *Br J Cancer*, 2012, 107(6):961-966. DOI:10.1038/bjc.2012.342.
- [353] Shitara K, Yamazaki K, Uetake H, et al. Randomized phase II study of regorafenib followed by cetuximab versus reverse sequence for wild-type KRAS metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and irinotecan (REVERCE) [J]. *J Clin Oncol*, 2018, 32(15 suppl):TPS3662-TPS.

## 附:结直肠癌肝转移诊断和综合治疗指南(V2018)修订专家名单(排名不分先后,以姓氏拼音排序)

## 编写组组长

蔡建强 中国医学科学院肿瘤医院  
 顾晋 北京大学肿瘤医院  
 秦新裕 复旦大学附属中山医院  
 王杉 北京大学人民医院  
 王锡山 中国医学科学院肿瘤医院  
 许剑民 复旦大学附属中山医院  
 张苏展 浙江大学医学院附属第二医院  
 张忠涛 首都医科大学附属北京友谊医院

## 编写组成员

巴一 天津医科大学附属肿瘤医院  
 卜建红 中华胃肠外科杂志  
 蔡建辉 河北省人民医院  
 蔡三军 复旦大学附属肿瘤医院  
 曾珊 中南大学湘雅医院  
 曾昭冲 复旦大学附属中山医院  
 陈功 广州中山大学附属肿瘤医院  
 陈凜 中国人民解放军总医院  
 陈子华 中南大学湘雅医院  
 陈宗祐 复旦大学附属华山医院  
 程洁敏 复旦大学附属中山医院  
 池畔 福建医科大学附属协和医院  
 戴广海 中国人民解放军总医院  
 戴勇 山东大学齐鲁医院  
 邓艳红 中山大学附属第六医院  
 丁克峰 浙江大学医学院附属第二医院  
 樊嘉 复旦大学附属中山医院  
 房学东 吉林大学中日联谊医院  
 傅传刚 同济大学附属东方医院  
 龚建平 华中科技大学附属同济医院  
 郝纯毅 北京大学肿瘤医院  
 何裕隆 中山大学附属第一医院  
 黄忠诚 湖南省人民医院  
 季加孚 北京大学肿瘤医院  
 贾宝庆 中国人民解放军总医院  
 姜可伟 北京大学人民医院  
 金晶 中国医学科学院肿瘤医院  
 孔大陆 天津医科大学附属肿瘤医院  
 兰平 中山大学附属第六医院  
 李德川 浙江省肿瘤医院  
 李国立 南京军区南京总医院  
 李进 同济大学附属东方医院  
 李乐平 山东省立医院  
 李云峰 云南省肿瘤医院  
 李志霞 首都医科大学北京同仁医院  
 梁后杰 第三军医大学附属西南医院  
 梁小波 山西省肿瘤医院  
 林锋 中山大学附属第六医院  
 林建江 浙江大学医学院附属第一医院  
 刘洪俊 山东省立医院  
 刘天舒 复旦大学附属中山医院  
 刘云鹏 中国医科大学附属第一医院  
 潘宏铭 浙江大学医学院附属邵逸夫医院  
 潘志忠 中山大学附属肿瘤医院  
 裴海平 中南大学湘雅医院

彭涛 广西医科大学第一附属医院  
 任黎 复旦大学附属中山医院  
 沈琳 北京大学肿瘤医院  
 宋纯 同济大学附属东方医院  
 宋天强 天津医科大学附属肿瘤医院  
 苏向前 北京大学肿瘤医院  
 孙益红 复旦大学附属中山医院  
 陶敏 苏州大学附属第一医院  
 田利国 中国实用外科杂志  
 万德森 中山大学肿瘤医院  
 汪建平 中山大学附属第六医院  
 王贵英 河北医科大学第四医院  
 王贵玉 哈尔滨医科大学附属第二医院  
 王海江 新疆医科大学附属肿瘤医院  
 王建华 复旦大学附属中山医院  
 王磊 中山大学附属第六医院  
 王新 第四军医大学西京病院  
 王雅杰 上海长海医院  
 王屹 北京大学人民医院  
 王自强 四川大学华西医院  
 韦烨 复旦大学附属中山医院  
 魏东 中国人民解放军第 150 医院  
 夏锋 第三军医大学附属西南医院  
 夏建国 江苏省人民医院  
 夏立建 山东省千佛山医院  
 邢宝才 北京大学肿瘤医院  
 熊斌 武汉大学中南医院  
 徐建明 中国人民解放军第 307 医院  
 徐农 浙江大学医学院附属第一医院  
 徐瑞华 中山大学附属肿瘤医院  
 徐烨 复旦大学附属肿瘤医院  
 徐泽宽 江苏省人民医院  
 徐忠法 山东省医学科学院附属医院  
 杨树军 河南省肿瘤医院  
 姚宏伟 首都医科大学附属北京友谊医院  
 叶颖江 北京大学人民医院  
 余佩武 第三军医大学附属西南医院  
 袁瑛 浙江大学医学院附属第二医院  
 张俊 上海交通大学医学院附属瑞金医院  
 张克亮 湖北省肿瘤医院  
 张卫 上海长海医院  
 张小田 北京大学肿瘤医院  
 张艳桥 哈尔滨医科大学附属肿瘤医院  
 张有成 兰州大学第二医院  
 章真 复旦大学附属肿瘤医院  
 赵青川 第四军医大学西京病院  
 赵任 上海交通大学医学院附属瑞金医院  
 郑树 浙江大学医学院附属第二医院  
 周爱萍 中国医学科学院肿瘤医院  
 周俭 复旦大学附属中山医院  
 周总光 四川大学华西医院

## 编写秘书

任黎

(执笔整理:许剑民 任黎)

(收稿日期:2018-05-27)